Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize Outcomes
Past Events

Accreditation/
Credit Designation

The University of Cincinnati and the Physicians' Education Resource®, LLC, (PER®) and are both accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians, and have collaborated to design and execute these live and enduring educational activities.

For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation:

The University of Cincinnati designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclaimer

Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize Outcomes


Saturday, June 3, 2017
7:00 PM - 9:00 PM

Dinner and registration: 6:30 PM – 7:00 PM

Hilton Chicago
Salon A 1 & 2 (Lower Level)
720 S Michigan Avenue
Chicago, IL 60605

Overview

Are you prepared to provide state-of-the-art care to the next patient who presents to your clinic with a soft tissue sarcoma (STS)? Don’t miss this opportunity to learn about the breakthroughs occurring in STS from a renowned group of experts. Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize Outcomes is a case-based, CME-certified, live symposium to be held adjunct to an annual oncology meeting in Chicago, Illinois.

Historically poor outcomes in patients with metastatic STS have led to therapeutic nihilism among some physicians. However, a greater appreciation of the heterogeneous, complex biologies across the many STS subtypes, as well as the development of new and emerging therapeutic approaches, are transforming the ways in which these malignancies are managed. Optimal treatment requires a highly skilled, multidisciplinary team that encompasses medicine, pathology, radiology, and surgery.

Join us to learn about what’s on the horizon in STS, and to gain up-to-date guidance on the delivery of cross-discipline care for patients with STS that leverages the resources of both community- and academic-based healthcare providers.

Key topics on the agenda include:

  • The latest advances in molecular diagnostic techniques
  • Key therapeutic targets in STS
  • Immunotherapeutic approaches in development for STS
  • Practice-changing clinical trial data in the settings of metastatic and unresectable STS
  • Key considerations during treatment planning
  • Potential clinical implications of new data

Target Audience

This educational program is directed toward medical, surgical, and radiation oncologists who manage patients with soft tissue sarcoma (STS). Nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with STS are also invited to participate.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  1. Detail methods to engage community-based oncologists to communicate with sarcoma specialists in the care of patients with soft tissue sarcoma in multiple lines of treatment
  2. Evaluate clinical circumstances that impact sequencing decision making along the disease continuum in the management of soft tissue sarcoma
  3. Explain disease heterogeneity in advanced soft tissue sarcomas, and its impact on treatment strategies and methods to overcome challenges to optimize diagnoses in the field
  4. Describe novel mechanistic approaches that have been applied to the treatment of patients with metastatic or unresectable soft tissue sarcoma

Program Chair

George D. Demetri, MD
Professor of Medicine, Harvard Medical School
Director, Ludwig Center at Harvard
Director, Center for Sarcoma and Bone Oncology
Dana-Farber Cancer Institute
Boston, MA


Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By